NDAORALCAPSULE
Approved
Jul 1974
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
3/8 — Basic
TIGAN (trimethobenzamide hydrochloride) by Pfizer is 12. First approved in 1974.
Drug data last refreshed 3d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TIGAN (trimethobenzamide HCl) is a small-molecule antiemetic approved in 1974 that acts on the chemoreceptor trigger zone in the medulla to suppress nausea and vomiting. It is indicated for Parkinson's disease-related nausea, where it addresses a common motor-therapy side effect rather than treating the underlying parkinsonian symptoms. The drug's mechanism remains partially obscure, with selective efficacy against certain emetic pathways.
LOE Approaching
As a 50-year-old product in LOE-approaching phase with no publicly reported spending, TIGAN operates with a minimal commercial team; roles are limited to maintenance of legacy market share.
Mechanism of Action
12.1 Mechanism of Action The mechanism of action of trimethobenzamide as determined in animals is obscure, but may involve the chemoreceptor trigger zone (CTZ), an area in the medulla oblongata through which emetic impulses are conveyed to the vomiting center; direct impulses to the vomiting center…
Worked on TIGAN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.